Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
Views & Analysis ‘Real world’ COPD trial gives GSK a dose of reality Salford Lung Study is a bold experiment, but hasn't fully paid off for GSK.
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
Articles Does real world evidence matter in Health Technology Assessm... Health Technology Assessment (HTA) agencies usually rely on randomised controlled trials for clinical data when evaluating drugs, but these do not always tell the entire story.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
